SavedAdd your journal

Journals / Abant Tıp Dergisi / 2026 / Cilt: 2 Sayı: 2

Rhabdomyolysis Related Statine and Fibrate Combination Theraphy: A Single Case

Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle

Ahsen Zeyrek İşçi(Abant İzzet Baysal Üniversitesi Tıp Fakültesi, İç Hastalıkları Ana Bilim Dalı, Bolu)
Gülali Aktaş(Abant İzzet Baysal Üniversitesi Tıp Fakültesi, İç Hastalıkları Ana Bilim Dalı, Bolu)
Sevim Karaçay(Abant İzzet Baysal Üniversitesi Tıp Fakültesi, İç Hastalıkları Ana Bilim Dalı, Bolu)
Haluk Şavlı(Abant İzzet Baysal Üniversitesi Tıp Fakültesi, İç Hastalıkları Ana Bilim Dalı, Bolu)
Pages
171–172
Publication Date
2013-05-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

İşçi, A. Z., Aktaş, G., Karaçay, S., Şavlı, H. (2013). Rhabdomyolysis Related Statine and Fibrate Combination Theraphy: A Single Case. Abant Tıp Dergisi, Cilt: 2 Sayı: 2, 171–172. https://doi.org/10.5505/abantmedj.2013.38039

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.
  2. Sathasivam S, Lecky B Statin induced myo- pathy.BMJ. 2008 Nov 6;337:2286
  3. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012 Jun;23(4):317-24
  4. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri- can College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Sta- tins.Stroke. 2002 Sep;33(9):2337-41
  5. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14
  6. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P Meta- analysis of drug-induced adverse events associated with intensive-dose statin the- rapy Clin Ther. 2007 Feb;29(2):253-60
  7. Antons KA, Williams CD, Baker SK, Phillips PS.Clinical perspectives of statin-induced rhabdomyolysis Am J Med. 2006 May;119(5):400-9
  8. Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospi- talized rhabdomyolysis with statin and fib- rate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9.
  9. Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstİl K, Bryniarski L, Császár A, Vanderbist F. Safety of a fixed- dose te/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012 Apr 1;32(4):281-91
  10. Davidson MH, Armani A, McKenney JM, Ja- cobson TA Safety considerations with fibra- te therapy Am J Cardiol. 2007 Mar 19;99(6A):3C-18C
  11. Baer AN, Wortmann RL Myotoxicity associ- ated with lipid-lowering drugs Curr Opin Rheumatol. 2007 Jan;19(1):67-73
  12. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur Dec;65(12):1169-74 2009